Y Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Y Intercept Hong Kong Ltd raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 193.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,151 shares of the biopharmaceutical company’s stock after purchasing an additional 12,617 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Ultragenyx Pharmaceutical were worth $1,064,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Alkeon Capital Management LLC increased its holdings in Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock worth $167,301,000 after acquiring an additional 769,884 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 8.7% in the second quarter. Federated Hermes Inc. now owns 2,107,025 shares of the biopharmaceutical company’s stock worth $86,599,000 after purchasing an additional 168,345 shares in the last quarter. Millennium Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 103.8% in the second quarter. Millennium Management LLC now owns 1,850,734 shares of the biopharmaceutical company’s stock valued at $76,065,000 after purchasing an additional 942,529 shares during the period. Baker BROS. Advisors LP lifted its stake in shares of Ultragenyx Pharmaceutical by 7.5% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,576,114 shares of the biopharmaceutical company’s stock valued at $87,553,000 after buying an additional 109,567 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in Ultragenyx Pharmaceutical by 16.9% in the 2nd quarter. Marshall Wace LLP now owns 1,133,100 shares of the biopharmaceutical company’s stock worth $46,570,000 after buying an additional 164,110 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. The trade was a 7.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emil D. Kakkis sold 8,273 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the transaction, the chief executive officer now owns 2,195,712 shares in the company, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 4.0 %

NASDAQ RARE opened at $46.89 on Friday. The stock’s 50-day simple moving average is $50.63 and its two-hundred day simple moving average is $49.05. Ultragenyx Pharmaceutical Inc. has a twelve month low of $37.02 and a twelve month high of $60.37. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of -7.25 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. During the same quarter in the previous year, the company posted ($2.23) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 42.3% compared to the same quarter last year. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RARE has been the topic of several recent research reports. Royal Bank of Canada restated an “outperform” rating and set a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. TD Cowen boosted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.46.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.